Virtual Library

Start Your Search

Yutao Liu

Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-47 - Clinical Characteristics and Outcome for Patients with Advanced Lung Adenocarcinoma Treated with First-Line Pemetrexed Plus Platinum (ID 13078)

      12:00 - 13:30  |  Author(s): Yutao Liu

      • Abstract
      • Slides


      To evaluate the efficacy and safety of pemetrexed combined with platinum first-line therapy for advanced lung adenocarcinoma, as well as the clinical factors influencing outcomes.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We retrospectively evaluated the data from 450 pemetrexed-treated patients with stage IIIb/IV lung adenocarcinoma that confirmed by cytology or histology from February 2011 to August 2017. Patients were divided into 2 groups according to the presence of maintenance therapy (yes or no) after the first-line chemotherapy. The primary endpoint was progression-free survival (PFS), secondary endpoints included objective response rate (ORR), disease control rates (DCR), and safety.

      4c3880bb027f159e801041b1021e88e8 Result

      A total of 292 received only first-line pemetrexed-based therapy, while 158 patients received maintenance pemetrexed after induction. The overall median PFS was 5.83 months (95% CI was 0.33 to 55.72 months). The maintenance treatment group had longer PFS (9.92 months, 95%CI: 3.98 to 5.21 months) than (P < 0.001) the non-maintenance treatment group (4.60 months, 95%CI: 8.70 to 11.14 months) after the first line chemotherapy (P < 0.001). The ORR and DCR of 450 patients with lung adenocarcinoma was 33.6% and 87.6%, respectively. Single-factor and multiple-factor analysis showed that positive mutation of epidermal growth factor receptor (EGFR), PS 0, exposure more than 4 cycles, and the addition of maintenance treatment were the positive prognostic factors for survival. The main adverse reactions of the patients were hematological toxicity, gastrointestinal reaction, abnormal and asthenia of liver function. However, low incidence of grade 3 or higher toxicity was seen in this study.

      8eea62084ca7e541d918e823422bd82e Conclusion

      First-line therapy with pemetrexed combined with platinum is safe and effective for advanced lung adenocarcinoma, and pemetrexed maintenance therapy has a better survival benefit.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.